Summit's ivonescimab data has sparked interest in BioNTech's BNT327, and its potential to follow a similar path and gain ...
Hosted on MSN17d
Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising?The stock has risen over 600% since the end of 2023, thanks to surprisingly positive trial results for a cancer therapy ...
Crescent Biopharma is advancing a drug its CEO claims is “purpose-built” to be a perfected version of Summit Therapeutics’ ...
JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 ...
Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...
Akeso begins patient enrollment in phase 3 trial of ivonescimab combination as first-line therapy for biliary tract tumours, compared to durvalumab: China Monday, November 4, 2024 ...
The latest update is out from Summit Therapeutics ( (SMMT) ).
The stock has risen over 600% since the end of 2023, thanks to surprisingly positive trial results for a cancer therapy called ivonescimab. The stock market has been pushing up Summit's stock ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback